SBC Medical is a high-quality, attractively valued small cap with a breakout setup and 37.2% upside to the analyst target, though it trades near its 52-week high and the latest quarter missed estimates.
Thesis pillars
- High Quality Compounder→Stable
- Deep Value With Upside→Stable
- Breakout Momentum→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026, based on the 10-K filed Mar 27, 2026
SBC Medical Group Holdings Inco (SBC) Stock Analysis
Inst Constrain edge
Conditional: analysts disagree (1.6× target spread) — below strong-conviction threshold. Size accordingly.
Industrials · Consulting Services
Buy now at $5.69. A.R:R 2.5:1 at $5.69 — the engine's gate value (upside to target $7.44 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$2 per share to target. Key risks: Near 52-week high (1.8% away); Sector modifier (Industrials): -0.7.
SBC Medical Group Holdings provides management services — advertising, staffing, and IT — to 237 franchisee aesthetic and cosmetic-surgery clinics run by medical corporations in Japan, plus 21 clinics it operates in Singapore and one in Vietnam. The company earned $173.6 million... Read more
Buy now at $5.69. A.R:R 2.5:1 at $5.69 — the engine's gate value (upside to target $7.44 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$2 per share to target. Key risks: Near 52-week high (1.8% away); Sector modifier (Industrials): -0.7. Chart setup: No clear chart pattern; technical signals are mixed. Deep value: 52% margin of safety. Extreme undervaluation. Score 7.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=industrials 0/10 self excluded). Suitability: aggressive.
About SBC Medical Group Holdings Inco
About SBC Medical Group Holdings Inco
SBC Medical Group Holdings generated $173.6 million in revenue and $51.0 million in net income for fiscal 2025, down from $205.4 million in revenue a year earlier, almost entirely through management-service fees paid by 237 franchisee cosmetic and aesthetic-surgery clinics in Japan. The company also operates 21 clinics in Singapore and one in Vietnam, and closed its sole U.S. clinic in Irvine, California in May 2025.
SBC earns nearly all of its revenue from franchise management-service fees charged to medical corporations (MCs) that own and operate the clinics carrying its Shonan Beauty Clinic and other brand names — covering services such as advertising, staffing, booking, procurement, and IT and technology licensing. Since April 2025 the company has shifted to a tiered, performance-based fee structure keyed to each clinic's medical-service category, operational tenure, monthly revenue, and patient volume, plus a customer-loyalty point program that also generates revenue when reward points expire unredeemed. The franchisee base is concentrated: SBC's subsidiaries hold franchisor-franchisee or service contracts with only seven core medical corporations plus a handful of newer service-contract counterparties, and relatives of CEO Yoshiyuki Aikawa control two-thirds of the voting members at these MCs. The company has recently diversified geographically through the 2024 acquisition of Aesthetic Healthcare Holdings in Singapore, a July 2025 acquisition of MB career lounge in Japan, a December 2025 majority stake in Tokyo-listed Waqoo, and an 18.2% equity investment in the U.S.-based OrangeTwist network.
Show full overview
SBC's franchise structure is shaped by a regulatory constraint distinct from a typical Western franchisor: Japan's Medical Care Act bars non-physician entities from holding voting control over the medical corporations that own its clinics, so SBC Medical Sub holds only an equity interest, or mochibun, entitling it to a share of residual assets rather than board votes at the MCs' general meetings of members. That structure leaves clinic-level governance in the hands of related parties — relatives of CEO Yoshiyuki Aikawa control two-thirds of the voting members across the seven core MCs — a dependency the 10-K flags explicitly as a franchisee-concentration risk factor, separate from ordinary competitive pressure.
See also: Industrials · Consulting Services
From SBC Medical Group Holdings Inco's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-10-30Recent Developments — SBC Medical Group Holdings Inco
Latest news
- NEWS SBC Medical Group at Q3 Investor Summit: growth re-accelerates By Investing.com - Investing.com Nigeria — Investing.com Nigeria positive
- NEWS SBC Medical Group at Q3 Investor Summit: growth re-accelerates By Investing.com - Investing.com — Investing.com positive
- NEWS SBC Medical Group at Q3 Investor Summit: growth re-accelerates By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS SBC Medical Group at Q3 Investor Summit: growth re-accelerates By Investing.com - Investing.com India — Investing.com India positive
- NEWS SBC Medical Group at Q3 Investor Summit: growth re-accelerates By Investing.com - Investing.com UK — Investing.com UK positive
Generated 2026-10-30T10:27:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerfranchisee medical corporations10-K Item 1A: 'We have substantial franchisee concentration.'
- MEDIUMGeographicJapan10-K Item 1A: 'a large percentage of revenues are concentrated with a limited number of franchisees that mainly operate the franchise locations in Japan'
Material Events(8-K, last 90d)
- 2026-07-14Item 3.01MEDIUMSBC lost Nasdaq board/Audit Committee independence compliance after director Mike Sayama did not seek re-election at the July 8, 2026 Annual Meeting; Nasdaq granted a cure period to regain compliance with Listing Rule 5605.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Buy now at $5.69. A.R:R 2.5:1 at $5.69 — the engine's gate value (upside to target $7.44 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$2 per share to target. Key risks: Near 52-week high (1.8% away); Sector modifier (Industrials): -0.7. Chart setup: No clear chart pattern; technical signals are mixed. Deep value: 52% margin of safety. Extreme undervaluation. Target $7.44 (+30.8%), stop $5.29 (−7.6%), A.R:R 2.5:1. Score 7.1/10, moderate confidence.
Take-profit target: $7.44 (+30.7% upside). Target $7.44 (+30.8%), stop $5.29 (−7.6%), A.R:R 2.5:1. Stop-loss: $5.29.
Near 52-week high (1.8% away); Sector modifier (Industrials): -0.7.
SBC Medical Group Holdings Inco trades at a P/E of 12.1 (forward 10.5). TrendMatrix value score: 7.8/10. Verdict: Strong Buy.
7 analysts cover SBC with a consensus score of 4.1/5. Average price target: $9.
What does SBC Medical Group Holdings Inco do?SBC Medical Group Holdings provides management services — advertising, staffing, and IT — to 237 franchisee aesthetic...
SBC Medical Group Holdings provides management services — advertising, staffing, and IT — to 237 franchisee aesthetic and cosmetic-surgery clinics run by medical corporations in Japan, plus 21 clinics it operates in Singapore and one in Vietnam. The company earned $173.6 million in revenue and $51.0 million in net income in fiscal 2025, collecting franchise fees mostly from a limited group of related-party medical corporations in Japan.